Qynapse Announces Research Collaborations for World MS Day

Marta Figueiredo PhD avatar

by Marta Figueiredo PhD |

Share this article:

Share article via email
Qynapse

Qynapse, a company that combines artificial intelligence with neuroimaging technology, is reaffirming its commitment to help advance multiple sclerosis (MS) research and care in recognition of World MS Day.

World MS Day is officially celebrated on May 30, with global events and activities designed to raise disease awareness.

With headquarters in France, the U.S., and Canada, Qynapse is focused on the development of technology and products — including QyScore — that help optimize diagnosis, prognosis, and monitoring of people with MS and other neurological conditions.

QyScore is the company’s cloud-based imaging software for the automated quantification of key magnetic resonance imaging (MRI) markers of central nervous system diseases such as MS, Alzheimer’s, and Parkinson’s.

The technology earned clearance for use in Europe in 2017 and in the U.S. in 2020.

“We are proud to participate in World MS Day, by reinforcing our commitment to MS research, but also by raising awareness on the importance of MRI education for MS patients which can contribute to a better understanding of the disease, optimizing patient experience and improving quality of life for people affected by MS,” Olivier Courrèges, Qynapse’s CEO, said in a press release.

As part of its sustained commitment, Qynapse announced a key collaboration with Brigham and Women’s Hospital (BWH) in Boston, a leading institution in neuroimaging and MS, to further advance MS research and clinical care.

BWH’s Multiple Sclerosis Center, one of the largest MS centers in the U.S., is known for providing advanced management and treatment options for people living with the disease. Its clinical research program aids in these efforts.

According to Charles R. G. Guttmann, MD, director of BWH’s center for neurological imaging, neuroimaging and particularly MRI have “revolutionized” clinicians’ abilities to efficiently diagnose MS.

“Today MRI scans provide the best biomarker for evidence of MS progression,” Guttmann said.

While there are several approved therapies for MS, “the symptoms and the response to treatment vary greatly from one individual to another, requiring a close monitoring and a tailored strategy for every patient,” said Guttmann, who also is an associate professor of radiology at the Harvard Medical School.

“We are pleased to collaborate with Qynapse to advance MS research with the ultimate goal of providing better services and effective treatment for people with MS,” Guttmann added.

For its part, the company is looking forward to working the the hospital’s staff.

“Qynapse is delighted to collaborate with Dr Guttmann and his team, expanding our scientific relationships with leading MS experts, to further advance the validation of our neuroimaging solutions for multiple sclerosis,” Courrèges said.

This year’s global campaign around World MS Day, created by the MS International Federation and its members in 2009 to raise MS awareness, is featuring virtual events and social media activities throughout early June.

The 2020–2022 theme is “connections” and the 2021 tagline is “I Connect, We Connect,” using the hashtag #MSConnections.

The Multiple Sclerosis Podcast



Video